Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results